Structural Basis for Inhibition of Urate Reabsorption in URAT1

Structural Basis for Inhibition of Urate Reabsorption in URAT1

Saved in:

Bibliographic Details
Main Authors:	Junping Fan, Wenjun Xie, Han Ke, Jing Zhang, Jin Wang, Haijun Wang, Nianxin Guo, Yingjie Bai, Xiaoguang Lei
Format:	Article
Language:	English
Published:	American Chemical Society 2025-02-01
Series:	JACS Au
Online Access:	https://doi.org/10.1021/jacsau.4c01188
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Molecular basis of the urate transporter URAT1 inhibition by gout drugs
by: Yang Suo, et al.
Published: (2025-06-01)

Mechanisms of urate transport and uricosuric drugs inhibition in human URAT1
by: Wenjun Guo, et al.
Published: (2025-02-01)

Molecular mechanisms of urate transport by the native human URAT1 and its inhibition by anti-gout drugs
by: Canrong Wu, et al.
Published: (2025-04-01)

Structural basis of urate transport by glucose transporter 9
by: Daiki Matsushita, et al.
Published: (2025-04-01)

Solving the mysteries of urate transport: structural insights into GLUT9 and URAT1
by: Mei Wang, et al.
Published: (2024-08-01)

Molecular mechanism of drug inhibition of URAT1
by: Zhuoya Yu, et al.
Published: (2025-07-01)

Sex-specific DNA methylation associations with circulating urate levels and BCG-induced urate changes
by: Zhaoli Liu, et al.
Published: (2025-07-01)

Urate-lowering therapy and kidney function
by: M. S. Eliseev
Published: (2023-04-01)

Urate-lowering therapy for heart failure
by: O. V. Zhelyabina, et al.
Published: (2019-09-01)

PHYTOPREPARATIONS IN THE PREVENTION AND TREATMENT OF URATE NEPHROLITHIASIS
by: N. G. Chaban, et al.
Published: (2017-12-01)

The Role of Urate in Calcium Stone Formation
by: Erika Critell, et al.
Published: (2024-11-01)

Real-life results of urate-driven pharmacotherapy with three urate lowering drugs in gout: allopurinol, febuxostat and benzbromarone
by: Ioana Hotea, et al.
Published: (2023-08-01)

Disorder of purine metabolism in the etiopathogenesis of urate nephrolithiasis
by: S. I. Vorotyntsev, et al.
Published: (2023-04-01)

Features of the course urate nephrolithiasis, comorbid with the metabolic syndrome
by: A. O. Hubar, et al.
Published: (2022-11-01)

Principles of urate-lowering therapy: eight steps to success
by: O. V. Zhelyabina, et al.
Published: (2023-07-01)

The beneficial effects of dapagliflozin on the course of experimental urate nephrolithiasis
by: V. Yu. Perfil’ev, et al.
Published: (2017-04-01)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
by: Taras S. Panevin, et al.
Published: (2020-12-01)

Urate lowering therapy in primary care: rheum for improvement
by: Emilie Schurenberg, et al.
Published: (2025-03-01)

Moxibustion inhibits inflammation in monosodium urate crystal-induced gouty arthritis model rats through metabolomic regulation
by: Yufeng Xie, et al.
Published: (2025-03-01)

Urate-lowering drugs in the treatment of gout: The unknown about the known
by: T. S. Panevin, et al.
Published: (2021-12-01)

Rational use of recommendations for urate-lowering therapy: clinical examples
by: M. S. Eliseev, et al.
Published: (2022-06-01)

Two cases of acute urate nephropathy in women with asymptomatic hyperuricemia
by: L. N. Yeliseyeva, et al.
Published: (2021-03-01)

Is Urate-lowering therapy a prevention of first gout episode?
by: Michał Szczepański, et al.
Published: (2025-07-01)

Chronic kidney disease: the role of hyperuricemia and the possibility of urate-lowering therapy
by: M. S. Eliseev
Published: (2018-04-01)

Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout
by: M. N. Chikina
Published: (2019-01-01)

Impact of urate-lowering therapy on quality of life indicators in patients with gout
by: M. N. Chikina, et al.
Published: (2021-06-01)

Behavioral Characteristics of Gout Patients and Their Impact on the Results of Urate Lowering Therapy
by: J. Chen, et al.
Published: (2021-04-01)

TSAT-Urated Insights: Clarifying the Complexities of Hereditary Hemochromatosis and Its Guidelines
by: Chiara Marcon, et al.
Published: (2024-12-01)

Identification of three distinct cell populations for urate excretion in human kidneys
by: Yoshihiko M. Sakaguchi, et al.
Published: (2024-01-01)

Pharmacokinetics and Ex Vivo Activity of 7-Methylxanthine, an Inhibitor of Monosodium Urate Crystallization
by: Miguel D. Ferrer, et al.
Published: (2025-06-01)

Assessment of the quality of life indicators in patients with urate nephrolithiasis comorbid with metabolic syndrome
by: S. I. Bilai
Published: (2022-04-01)

Modulation of genetic associations with serum urate levels by body-mass-index in humans.
by: Jennifer E Huffman, et al.
Published: (2015-01-01)

SLC2A9 is a high-capacity urate transporter in humans.
by: Mark J Caulfield, et al.
Published: (2008-10-01)

Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy
by: Maria Antonietta D'Agostino, et al.
Published: (2020-02-01)

Gout management: Patent analytics and computational drug design explores URAT1 inhibitors landscape
by: Jiaxin Zhang, et al.
Published: (2025-01-01)

Urate-lowering effects of polyphenolic compounds in animal models: systematic review and meta-analysis
by: Jianhong Chen, et al.
Published: (2025-08-01)

Engineered Escherichia coli Nissle 1917 with urate oxidase and an oxygen-recycling system for hyperuricemia treatment
by: Rui Zhao, et al.
Published: (2022-12-01)

Stachydrine from Natural Foods Alleviates Hyperuricemia by Modulating Renal Urate Transporters and Suppressing Mitochondrial Oxidative Stress
by: Jian Guo, et al.
Published: (2025-05-01)

Should all people starting urate-lowering therapy for gout receive anti-inflammatory prophylaxis?
by: Edward Roddy, et al.
Published: (2024-11-01)

Prospects of anti-inflammatory and urate-lowering therapy of gout: A vector from the past to the future
by: A. A. Garanin, et al.
Published: (2022-05-01)